Product Attributes CAS # : 218949-48-5 Molecular Formula : C221H366N72O67S Sequence (AA) : Tyr-DAla-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 Molecular Weight : 5135.87 g/mol PubChem CID : 16137828 Half-Life : ~30 minutes (biological activity extended up to 2 hours) Synonyms : TH9507, Tesamorelin acetate, Egrifta SV WR, hGRF / GHRH / Growth hormone-releasing factor analog Type : Synthetic GHRH analog Research Focus : Weight Loss, Anti-Age, Endocrine Regulation Scientific References Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data Human RCT The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV Human RCT Effects of tesamorelin on nonalcoholic fatty liver disease in HIV: a randomized, double-blind, multicenter trial Human RCT Tesamorelin improves fat quality independent of changes in fat quantity Human observational Tesamorelin, a human growth hormone releasing factor analogue Review Growth hormone and tesamorelin in the management of HIV disease Review Effects of tesamorelin on neurocognitive impairment in persons with HIV Human RCT Tesamorelin improves fat quality independent of changes in fat quantity Human RCT Tesamorelin LiverTox NCBI Bookshelf Review Tesamorelin as an adjunct to exercise for improving physical function and muscle health in older adults with HIV Ongoing study Included In The Box Every product arrives in a premium, custom-designed PEPTIDE.Power box , engineered for convenience, hygiene, and safe storage in your refrigerator
Supposedly the years of going to bed hungry are receding into the rear-view mirror
How does the oral Wegovy pill approval in December 2025 affect the GLP-1 patent landscape
Lawsuits point to evidence that drugmakers were aware of more long-term risks than they disclosed, continuing to market GLP-1 drugs as safe for widespread use
24-48 hours: You may feel slightly less hungry within the first 1-2 days of using semaglutide, although this is not typically expected for most people
If you are unsure whether you meet these requirements, contact our Ozempic lawsuit attorneys for a free case evaluation
